雌、孕激素受体及癌基因C-erbB-2在150例乳腺癌中的表达及与临床治疗预后的关系  

Relationship Between the Expression and Clinical Treatment & Prognosis of Estrogen Receptor,Progesterone Receptor and Cancer Gene C-erbB-2

作　　者：董亚文[1] 孙华[1] 

机构地区：[1]甘肃省嘉峪关市酒钢医院病理科,甘肃嘉峪关735100

出　　处：《黑龙江医学》2014年第1期8-9,共2页Heilongjiang Medical Journal

摘　　要：目的 探讨雌激素受体（ER）、孕激素受体（PR）及癌基因C-erbB-2在乳腺癌生物学行为中所起的作用,指导临床对乳腺癌患者进行内分泌治疗及其预后的判断.方法 本研究收集1999~2010年在有完整随访资料的150例乳腺癌石蜡标本进行免疫组织化学染色检测ER、PR、C-erbB-2抗体.结果 其中60例ER阳性患者内分泌治疗后,ER、PR阳性、C-erbB-2阴性者5年存活率为73.3%（22/30）、复发率为4.5%（1/22）,ER、PR阳性,C-erbB-2阳性者5年生存率为36.8%（7/19）、复发率为42.9%（3/7）,ER阳性、PR阴性、C-erbB-2阴性者5年生存率为63.6%（7/11）、复发率为20.0%（1/5）,60例经内分泌治疗患者5年总生存率为60.0%,总复发率为14.7%.结论 通过联合检测ER、PR、C-erbB-2基因与乳腺癌临床、病理因素之间的关系,指导临床术后选择合适的药物进行辅助治疗,降低肿瘤复发风险,提高患者的生存率.Objective To study the effect of ER, PR and C - erbB - 2 on breast cancer biology to provide reference for endocrine therapy prognosis judgment for breast cancer patients. Methods Collecting 150 cases of breast cancer specimens of paraffin for immunohistochemi- cal staining detection of ER, PR, C - erbB - 2 antibodies from 1999 to 2010. Results Among 60 patients with ER positive endocrine therapy, ER and PR positive, C - erbB - 2 negative 5 - year survival rate was 73.3 % （22/30）, the recurrence rate was 4. 5 % （ 1/22）, ER and PR positive and C - erbB -2 5 - year survival rate was 36. 8% （7/19）, the recurrence rate was 42. 9% （3/7）, ER positive, negative and C - erbB - PR 2 negative 5 - year survival rate was 63.6% （7/11）, and the recurrence rate was 20.0% （ 1/5 ）. 5-year survival rate of 60 patients with endocrine treatment was 60. 0%, and the total rate of relapse rate was 14. 7%. Conclusion Through joint detection of ER, PR, C -erbB -2 gene and the relationship between the clinical and pathological factors of breast cancer, appropriate drugs for adjuvant treatment after surgery is guided, to reduce the risk of tumor recurrence and improve survival rate.

关 键 词：乳腺癌 雌激素受体 孕激素受体 癌基因C-ERBB-2 内分泌治疗 预后 

分 类 号：R737.9[医药卫生—肿瘤]